SCHEMBL30878614

SCHEMBL30878614

Cc1cccc(OC(=O)C2CCNC2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
SSTR4 P31391 2/20 0.49
SSTR1 P30872 1/20 0.49
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
PPARG P37231 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
POLB P06746 1/20 0.47
HTR2C P28335 3/20 0.44
HTR2B P41595 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4544899 0.85 LMNA (0.61) LMNAMEN1ALDH1A1PPARGKMT2A
SCHEMBL27947134 0.85 LMNA (0.61) LMNAMEN1ALDH1A1PPARGKMT2A
SCHEMBL28061413 0.84 KMT2A (0.50) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5813373 0.83 ELANE (0.51) KMT2ASMN1; SMN2POLBL3MBTL1MAPT
SCHEMBL28167146 0.83 ELANE (0.51) KMT2ASMN1; SMN2POLBL3MBTL1MAPT
SCHEMBL30477041 0.83 POLB (0.47) POLBL3MBTL1SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL20703828 0.76 POLB (0.49) LMNAKMT2ASMN1; SMN2POLBHTR2C
SCHEMBL12266961 0.75 MEN1 (0.52) LMNAMEN1ALDH1A1PPARGKMT2A
SCHEMBL29175598 0.75 HTT (0.50) KMT2ASMN1; SMN2POLBHTR2CHTR2B
SCHEMBL9026265 0.75 LMNA (0.56) LMNAMEN1ALDH1A1PPARGKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587126-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION Amphista Therapeutics Ltd (GB) 2025-07-23 EP disclosed
WO-2024057021-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2024-03-21 WO disclosed